BMO Capital Markets initiated coverage on shares of ARMO Biosciences (NASDAQ:ARMO) in a research report released on Tuesday morning. The brokerage issued an outperform rating and a $75.00 price target on the stock.
Separately, Jefferies Group began coverage on shares of ARMO Biosciences in a research report on Tuesday. They issued a buy rating and a $61.00 price objective for the company.
Shares of ARMO Biosciences (ARMO) opened at $54.34 on Tuesday. ARMO Biosciences has a 52-week low of $27.00 and a 52-week high of $57.19.
WARNING: “BMO Capital Markets Initiates Coverage on ARMO Biosciences (ARMO)” was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thestockobserver.com/2018/02/21/bmo-capital-markets-initiates-coverage-on-armo-biosciences-armo.html.
ARMO Biosciences Company Profile
ARMO Biosciences, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company’s platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients.
Receive News & Ratings for ARMO Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARMO Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.